Coronary Artery DiseasePhase 3REDUCEDNCT01031095
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
A Phase 3 study testing coronary intervention in people with Coronary Artery Disease, run by Bursa Postgraduate Hospital at 1 site in Turkey (Türkiye).
Trial summary
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- coronary intervention
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Jun 2009to Jun 2010
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The patients; who have planned elective PCI and have had written informed consent for participation to study.
- The native coronary artery;
- lesion with narrowing >=70%,
- lesion without thrombus
- no left main coronary artery (LMCA) lesion
- no chronic total occlusion lesion
Who cannot join
- Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin
- Patients who performed primary PCI
- Patients with acute coronary syndrome
- Patients with have a history of myocardial infarction (MI) for two weeks
- Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours
- Patients on warfarin therapy
- Patients who have bleeding diathesis, or have high risk for bleeding.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Bursa, 16320
About this study
Official title: A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention
The hypothesis:
Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
Read the detailed description
Aim:
Primary objective:To evaluate the efficiency and safety of low dose intracoronary unfractioned heparin (UFH) on elective percutaneous coronary intervention (PCI).
Secondary objective:
- To evaluate the effect of low dose intracoronary UFH on myocardial ischemia after PCI.
- To evaluate the effect of low dose intracoronary UFH on bleeding complications after PCI.
- To evaluate the cost-effectivity of low dose intracoronary UFH on elective PCI
Study central:
- Bursa Postgraduate Hospital, Cardiology Clinic
Study population:
- we planned to enrol 200 patients.
- Patients will randomise in two groups (control group:100 patients, study group:100 patients)
Study works:-Write case report form for all patients
- Control for inclusion criteria
- Demographic data (age, gender)
- Height, weight, BMI and glomerular filtration rate (GFR)
- Risk factors
- laboratory data (biochemical and hematologic)
- Medication history
- Echocardiographic data
- Angiographic data
- Procedure time
- PCI data(vessel diameter, stent diameter, lesion and stent length, performed percutaneous transluminal coronary angioplasty (PTCA) or not, etc)
- Before and after procedure (activated clotting time) ACT value
- Before and after procedure troponin I (TnI) and Creatine kinase MB (CKMB) levels
- Note complication (MACE, bleeding, hematoma etc)
- Note femoral compression time. 4 weeks later note the first control data.
Six months later note the second control data.
- Conditions
- Coronary Artery Disease
- Being tested
- coronary intervention
- Keywords
- percutaneous coronary intervention, low dose intracoronary heparin
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
coronary interventionOther
elective coronary intervention
| Study group | Role | What they receive |
|---|---|---|
| Low dose intracoronary heparin | Experimental | Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin Receives: Other: coronary intervention |
| Standard treatment arm | Active comparator | Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin Receives: Other: coronary intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Adverse Cardiac Events
Measured: 30 days
Major Adverse Cardiac Event
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2009 (estimated)
- Study startJun 2009
- Primary completionDec 2009
- Study completionJun 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bursa Postgraduate Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hasan ARI, Bursa Postgraduate Hospital
- Investigators
- Hasan Arı, MD, Study director, Bursa Postgraduate Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01031095
- Sponsor's protocol ID
- BYİEAH1
- Acronym
- REDUCED
- Status last verified
- Dec 2013
- First submitted
- 11 Dec 2009
- Last updated
- 30 Jan 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, Ambrosini V, Campopiano E, Popusoi G, Biondi Zoccai G, Rubino P. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008 Oct 14;52(16):1293-8. doi: 10.1016/j.jacc.2008.07.026.
PubMed 18929239Ari H, Kivac E, Ari S, Emlek N, Cetinkaya S, Celiloglu N, Sarigul OY, Aydin C, Akkaya M, Koca V, Bozat T, Gurdogan M. The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation thErapy to low Dose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention. Acta Cardiol. 2014 Dec;69(6):619-27. doi: 10.1080/ac.69.6.1000004.
PubMed 25643432
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention
- ClinicalTrials.gov ID
- NCT01031095
- Acronym / sponsor ID
- REDUCED / BYİEAH1
- Conditions
- Coronary Artery Disease
- Keywords
- percutaneous coronary intervention, low dose intracoronary heparin
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Bursa Postgraduate HospitalUniversity, hospital or other
- Study start
- Jun 2009
- Primary completion
- Dec 2009 (actual)
- Study completion
- Jun 2010 (actual)
- First posted
- 14 Dec 2009 (estimated)
- Results
- Posted 10 Oct 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The hypothesis:
Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
Detailed description
Aim:
Primary objective:To evaluate the efficiency and safety of low dose intracoronary unfractioned heparin (UFH) on elective percutaneous coronary intervention (PCI).
Secondary objective:
- To evaluate the effect of low dose intracoronary UFH on myocardial ischemia after PCI.
- To evaluate the effect of low dose intracoronary UFH on bleeding complications after PCI.
- To evaluate the cost-effectivity of low dose intracoronary UFH on elective PCI
Study central:
- Bursa Postgraduate Hospital, Cardiology Clinic
Study population:
- we planned to enrol 200 patients.
- Patients will randomise in two groups (control group:100 patients, study group:100 patients)
Study works:-Write case report form for all patients
- Control for inclusion criteria
- Demographic data (age, gender)
- Height, weight, BMI and glomerular filtration rate (GFR)
- Risk factors
- laboratory data (biochemical and hematologic)
- Medication history
- Echocardiographic data
- Angiographic data
- Procedure time
- PCI data(vessel diameter, stent diameter, lesion and stent length, performed percutaneous transluminal coronary angioplasty (PTCA) or not, etc)
- Before and after procedure (activated clotting time) ACT value
- Before and after procedure troponin I (TnI) and Creatine kinase MB (CKMB) levels
- Note complication (MACE, bleeding, hematoma etc)
- Note femoral compression time. 4 weeks later note the first control data.
Six months later note the second control data.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low dose intracoronary heparin | Experimental | Other: coronary interventionLow dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin |
| Standard treatment arm | Active comparator | Other: coronary interventionStandard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- The patients; who have planned elective PCI and have had written informed consent for participation to study.
- The native coronary artery;
Key exclusion criteria (7 listed)
- Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin
- Patients who performed primary PCI
- Patients with acute coronary syndrome
- Patients with have a history of myocardial infarction (MI) for two weeks
- Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| coronary interventionelective coronary intervention | Other | Low dose intracoronary heparin, Standard treatment arm |
Primary outcome
Major Adverse Cardiac Events
Time frame: 30 days
Major Adverse Cardiac Event
Time frame: 30 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 18929239Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, Ambrosini V, Campopiano E, Popusoi G, Biondi Zoccai G, Rubino P. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008 Oct 14;52(16):1293-8. doi: 10.1016/j.jacc.2008.07.026.
- Derived from this study: PubMed 25643432Ari H, Kivac E, Ari S, Emlek N, Cetinkaya S, Celiloglu N, Sarigul OY, Aydin C, Akkaya M, Koca V, Bozat T, Gurdogan M. The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation thErapy to low Dose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention. Acta Cardiol. 2014 Dec;69(6):619-27. doi: 10.1080/ac.69.6.1000004.
Related trials for Coronary Artery Disease
Not yet recruitingObservational study
Assessment of Transnational Performance of the Universal Cardiac Surgical Risk Score Across International Sites
Heart Valve Diseases, Cardiac Surgical Procedures
Not yet recruiting
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Coronary In-stent Restenosis, Coronary Artery Disease
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hasan Arı, MD study director
Bursa Postgraduate Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing coronary intervention in people with Coronary Artery Disease, run by Bursa Postgraduate Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Oct 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Adverse Cardiac Events (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01031095, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2014.